Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology

Neoplasia

Volumn 7, Issue 7, 2005, Pages 678-687

  Zhao, Dawen ^a   Jiang, Lan ^a   Hahn, Eric W ^a   Mason, Ralph P ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anti angiogenesis; Continuous low dose (metronomic) chemotherapy; Immunohistochemistry; Magnetic resonance imaging (MRI); Prostate tumor

Indexed keywords

CYCLOPHOSPHAMIDE; THALIDOMIDE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTINUOUS INFUSION; CONTINUOUS LOW DOSE CHEMOTHERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; GENETIC HETEROGENEITY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LOW DRUG DOSE; METRONOMIC CHEMOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE TUMOR; RAT; TREATMENT INDICATION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 23244451977     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04757     Document Type: Article

References (42)

1. Browder T, Buttertield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, and Folkman J (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60, 1878-1886.
2. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, and Kerbel RS (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without over toxicity. J Clin Invest 105, R15-24.
3. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, and Kerbel RS (2002). Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through drinking water. Cancer Res 62, 2731-2735.
4. Hermans IF, Chong TW, Palmowski MJ, Harris AL, and Cerundolo V (2003). Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 63, 8408-8413.
5. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, et al. (2002). Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13, 73-80.
6. Kerbel RS and Kamen BA (2004). The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4, 423-436.
7. Small EJ, Srinivas S, Egan B, McMillan A, and Rearden TP (1996). Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J Clin Oncol 14, 1617-1625.
8. Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, Olson K, and Smith DC (2003). Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer 98, 1603-1610.
9. D'Amato RJ, Loughnan MS, Flynn E, and Folkman J (1994). Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91, 4082-4085.
10. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, et al. (2001). A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7, 1888-1893.
11. Ng SS, Gutschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K, and Figg WD (2003). Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res 63, 3189-3194.
12. Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, Nalcioglu O, Raghunand N, Ronen SM, Ross BD, and Swartz HM (2000). Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2, 152-165.
13. Gillies RJ, Bhujwalla ZM, Evelhoch J, Garwood M, Neeman M, Robinson SP, Sotak CH, and Van Der Sanden B (2000). Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia 2, 139-151.
14. Tofts PS (1997). Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7, 91-101.
15. Port RE, Knopp MV, Hoffmann U, Milker-Zabel S, and Brix G (1999). Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging. J Magn Reson Imaging 10, 233-241.
16. Bhujwalla ZM, Artemov D, Natarajan K, Solaiyappan M, Kollars P, and Kristjansen PE (2003). Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 9, 355-362.
17. Robinson SP, McIntyre DJ, Checkley D, Tessier JJ, Howe FA, Griffiths JR, Ashton SE, Ryan AJ, Blakey DC, and Waterton JC (2003). Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 88, 1592-1597.
18. Gross S, Gilead A, Scherz A, Neeman M, and Salomon Y (2003). Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat Med 9, 1327-1331.
19. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, and Griffiths JR (2001). Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 14, 497-506.
20. Hahn EW, Peschke P, Mason RP, Babcock EE, and Antich PP (1993). Isolated tumor growth in a surgically formed skin pedicle in the rat: a new tumor model for NMR studies. Magn Reson Imaging 11, 1007-1017.
21. Peschke P, Hahn EW, Wenz F, Lohr F, Braunschweig F, Wolber G, Zuna I, and Wannenmacher M (1998). Differential sensitivity of three sublines of the rat Dunning prostate tumor system R3327 to radiation and/or local tumor hyperthermia. Radiat Res 150, 423-430.
22. Heckl S, Pipkorn R, Waldeck W, Spring H, Jenne J, von der Lieth CW, Corban-Wilhelm H, Debus J, and Braun K (2003). Intracellular visualization of prostate cancer using magnetic resonance imaging. Cancer Res 63, 4766-4772.
23. Zhao D, Ran S, Constantinescu A, Hahn EW, and Mason RP (2003). Tumor oxygen dynamics: correlation of in vivo MRI with histological findings. Neoplasia 5, 308-318.
24. Weidner N (1995). Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147, 9-19.
25. Taylor JS and Reddick WE (2000). Evolution from empirical dynamic contrast-enhanced magnetic resonance imaging to pharmacokinetic MRI. Adv Drug Deliv Rev 41, 91-110.
26. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, and Rustin GJ (2003). Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21, 2831-2842.
27. Zhao D, Jiang L, Hahn EW, and Mason RP (2005). Tumor physiological response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys (in press).
28. Poptani H, Bansal N, Graham RA, Mancuso A, Nelson DS, and Glickson JD (2003). Detecting early response to cyclophosphamide treatment of RIF-1 tumors using selective multiple quantum spectroscopy (SelMQC) and dynamic contrast enhanced imaging. NMR Biomed 16, 102-111.
29. Evelhoch JL (1999). Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10, 254-259.
30. Jiang L, Zhao D, Constantinescu A, and Mason RP (2004). Comparison of BOLD contrast and Gd-DTPA dynamic contrast-enhanced imaging in rat prostate tumor. Magn Reson Med 51, 953-960.
31. 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 73, 61-64.
32. 13C magnetic resonance spectroscopy, Eppendorf electrode, and redox scanning. Cancer Res 63, 8813-8820.
33. Abramovitch R, Dafni H, Smouha E, Benjamin LE, and Neeman M (1999). In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res 59, 5012-5016.
34. Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X, Moss KG, Louie SG, Mendel DB, and Cherrington JM (2002). SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 16, 681-690.
35. Bocci G, Francia G, Man S, Lawler J, and Kerbel RS (2003). Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100, 12917-12922.
36. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, and Kalluri R (2004). Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64, 1570-1574.
37. Bocci G, Nicolaou KC, and Kerbel RS (2002). Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62, 6938-6943.
38. Wang J, Lou P, Lesniewski R, and Henkin J (2003). Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14, 13-19.
39. Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, and Stadler WM (2002). A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95, 1629-1636.
40. Mason RP, Constantinescu A, Hunjan S, Le D, Hahn EW, Antich PP, Blum C, and Peschke P (1999). Regional tumor oxygenation and measurement of dynamic changes. Radiat Res 152, 239-249.
41. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, et al. (2004). Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22, 2532-2539.
42. Drake MJ, Robson W, Mehta P, Schofield I, Neal DE, and Leung HY (2003). An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 88, 822-827.